DK3079719T3 - ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf - Google Patents

ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number: DK3079719T3
Authority: DK; Denmark
Prior art keywords: siglec; antibodies; methods
Prior art date: 2013-12-09

Application number

DK14869424T

Other languages

English (en)

Inventor

Christopher R Bebbington

Rustom Falahati

Fernandes Carolina Rita Sousa

David John Matthews

Nenad Tomasevic

Jason Williams

John Leung

Original Assignee

Allakos Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-09

Filing date

2014-12-09

Publication date

2019-11-18

2014-12-09 Application filed by Allakos Inc filed Critical Allakos Inc

2019-11-18 Application granted granted Critical

2019-11-18 Publication of DK3079719T3 publication Critical patent/DK3079719T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

DK14869424T 2013-12-09 2014-12-09 ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf DK3079719T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361913891P	2013-12-09	2013-12-09
PCT/US2014/069409 WO2015089117A1 (en)	2013-12-09	2014-12-09	Anti-siglec-8 antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK3079719T3 true DK3079719T3 (da)	2019-11-18

Family

ID=53371783

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14869424T DK3079719T3 (da)	2013-12-09	2014-12-09	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf

Country Status (23)

Country	Link
US (4)	US9546215B2 (da)
EP (2)	EP3611191A1 (da)
JP (4)	JP6549143B2 (da)
KR (3)	KR20210125114A (da)
CN (3)	CN105916519B (da)
AU (2)	AU2014363944B2 (da)
BR (1)	BR112016013109B1 (da)
CA (1)	CA2930886A1 (da)
CY (1)	CY1122329T1 (da)
DK (1)	DK3079719T3 (da)
ES (1)	ES2758508T3 (da)
HR (1)	HRP20192052T1 (da)
HU (1)	HUE047283T2 (da)
IL (3)	IL298470A (da)
LT (1)	LT3079719T (da)
NZ (1)	NZ720769A (da)
PL (1)	PL3079719T3 (da)
PT (1)	PT3079719T (da)
RS (1)	RS59567B1 (da)
SG (2)	SG10201808835QA (da)
SI (1)	SI3079719T1 (da)
WO (1)	WO2015089117A1 (da)
ZA (1)	ZA201603435B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4014995A1 (en) *	2014-02-28	2022-06-22	Allakos Inc.	Methods and compositions for treating siglec-8 associated diseases
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CA2987797A1 (en)	2015-06-17	2016-12-22	Christopher Robert Bebbington	Methods and compositions for treating fibrotic diseases
US10604577B2 (en) *	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018129400A1 (en) *	2017-01-06	2018-07-12	Allakos Inc.	Methods and compositions for treating chronic obstructive pulmonary disorder
US20200270344A1 (en) *	2017-05-05	2020-08-27	Allakos Inc.	Methods and compositions for treating inflammatory gastrointestinal disorders
CN110831628A (zh) *	2017-05-05	2020-02-21	爱乐科斯公司	用于治疗过敏性眼病的方法和组合物
CA3099338A1 (en) *	2018-05-04	2019-11-07	Christopher Robert Bebbington	Methods and compositions for treating chronic urticaria
KR20210126084A (ko) *	2019-02-15	2021-10-19	알라코스 인크.	비만 세포 위염, 비만 세포 식도염, 비만 세포 장염, 비만 세포 십이지장염 및/또는 비만 세포 위장염을 치료하기 위한 방법 및 조성물
JP2022542472A (ja) *	2019-08-02	2022-10-03	アラコスインコーポレイテッド	抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法
WO2021081411A1 (en) *	2019-10-24	2021-04-29	Allakos Inc.	Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
WO2021247821A1 (en) *	2020-06-03	2021-12-09	The Wistar Institute Of Anatomy And Biology	Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy
WO2022061032A1 (en) *	2020-09-17	2022-03-24	Allakos Inc.	Methods and compositions for treating viral infection
WO2022215566A1 (ja) *	2021-04-05	2022-10-13	国立大学法人筑波大学	アレルギー性疾患の予防又は治療剤
WO2023215907A1 (en) *	2022-05-06	2023-11-09	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Inhibiting mast cell activation by binding sialic acid-binding immunoglobulin-like lectin-9 (siglec-9)
WO2024043940A1 (en) *	2022-08-25	2024-02-29	Allakos Inc.	Methods and compositions for treating atopic dermatitis

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
EP0435911B1 (en)	1988-09-23	1996-03-13	Cetus Oncology Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5891693A (en)	1990-01-25	1999-04-06	Alusuisse Holdings A.G.	Recombinant DNA methods vectors and host cells
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en)	1990-11-09	1993-11-23	Board Of Regents, The University Of Texas System	Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en)	1990-11-09	1996-04-16	Board Of Regents, The University Of Texas System	Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr)	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US7018809B1 (en)	1991-09-19	2006-03-28	Genentech, Inc.	Expression of functional antibody fragments
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
ATE503496T1 (de)	1992-02-06	2011-04-15	Novartis Vaccines & Diagnostic	Biosynthetisches bindeprotein für tumormarker
CA2118508A1 (en)	1992-04-24	1993-11-11	Elizabeth S. Ward	Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2091684T3 (es)	1992-11-13	1996-11-01	Idec Pharma Corp	Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5885573A (en)	1993-06-01	1999-03-23	Arch Development Corporation	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US5639635A (en)	1994-11-03	1997-06-17	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6027888A (en)	1996-04-05	2000-02-22	Board Of Regents, The University Of Texas System	Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US6083715A (en)	1997-06-09	2000-07-04	Board Of Regents, The University Of Texas System	Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
EP0994903B1 (en)	1997-06-24	2005-05-25	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
BR9813365A (pt)	1997-12-05	2004-06-15	Scripps Research Inst	Método para produção e humanização de um anticorpo monoclonal de rato
PT1068241E (pt)	1998-04-02	2007-11-19	Genentech Inc	Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
EP2364997A3 (en)	1999-01-15	2012-07-04	Genentech, Inc.	Polypeptide variants with altered effector function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
ES2420835T3 (es)	1999-04-09	2013-08-27	Kyowa Hakko Kirin Co., Ltd.	Procedimiento para controlar la actividad de las moléculas inmunofuncionales
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PRODUCING A POLYPEPTIDE
JP4860877B2 (ja) *	2000-03-07	2012-01-25	ジョンズ・ホプキンス・ユニバーシティ	シアロアドへジンファクター−２抗体
US20030092091A1 (en) *	2000-03-07	2003-05-15	Abrahamson Julie A.	Sialoadhesin factor-2 antibodies
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2727425T3 (es)	2000-12-12	2019-10-16	Medimmune Llc	Moléculas con semividas prolongadas, composiciones y usos de las mismas
NZ592087A (en)	2001-08-03	2012-11-30	Roche Glycart Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
JP2005532253A (ja)	2001-10-25	2005-10-27	ジェネンテック・インコーポレーテッド	糖タンパク質組成物
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
EP1498485A4 (en)	2002-04-09	2006-09-06	Kyowa Hakko Kogyo Kk	CELLS WITH MODIFIED GENOM
JPWO2003084569A1 (ja)	2002-04-09	2005-08-11	協和醗酵工業株式会社	抗体組成物含有医薬
US20040259150A1 (en)	2002-04-09	2004-12-23	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1500698B1 (en)	2002-04-09	2011-03-30	Kyowa Hakko Kirin Co., Ltd.	Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
AU2003236019A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4351674B2 (ja)	2002-12-16	2009-10-28	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体とその使用法およびその使用
AU2004279742A1 (en)	2003-10-08	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Fused protein composition
JPWO2005035778A1 (ja)	2003-10-09	2006-12-21	協和醗酵工業株式会社	α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
WO2005044859A2 (en)	2003-11-05	2005-05-19	Glycart Biotechnology Ag	Cd20 antibodies with increased fc receptor binding affinity and effector function
WO2005053742A1 (ja)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	抗体組成物を含有する医薬
JP4782700B2 (ja)	2004-01-20	2011-09-28	カロバイオスファーマシューティカルズインコーポレイティッド	最低限必須な結合決定基を用いた抗体特異性の移入
US7745421B2 (en)	2004-05-25	2010-06-29	The Johns Hopkins University	Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells
AU2005306502B2 (en)	2004-11-16	2012-11-15	Humanigen, Inc.	Immunoglobulin variable region cassette exchange
US8357671B2 (en)	2005-11-10	2013-01-22	James Paulson	High affinity Siglec ligands
WO2007056870A1 (en)	2005-11-21	2007-05-24	The Governors Of The University Of Alberta	Methods and compositions for pharmacologically controlled targeted immunotherapy
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CA2723197C (en)	2008-05-02	2017-09-19	Seattle Genetics, Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
MX2012002427A (es) *	2009-08-28	2012-08-03	Vlst Corp	Anticuerpos anticina que se unen a quimiocinas cc multiples.
MX2012003404A (es)	2009-09-22	2012-09-12	Volker Sandig	Procedimiento para producir moleculas que contienen estructuras de glicano especializadas.
US8586044B2 (en)	2010-05-28	2013-11-19	Northwestern University	Treatment of chronic pelvic pain syndrome
EP2465873A1 (en)	2010-12-16	2012-06-20	Deutsches Rheuma-Forschungszentrum Berlin	Eosinophils as a therapeutic target
AU2012226398B9 (en) *	2011-03-06	2017-04-13	Merck Serono S.A.	Low fucose cell lines and uses thereof
WO2013120066A1 (en) *	2012-02-10	2013-08-15	University Of Maryland, Baltimore	Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
EP4014995A1 (en) *	2014-02-28	2022-06-22	Allakos Inc.	Methods and compositions for treating siglec-8 associated diseases
US10604577B2 (en) *	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
CN110831628A (zh) *	2017-05-05	2020-02-21	爱乐科斯公司	用于治疗过敏性眼病的方法和组合物

2014
- 2014-12-09 LT LT14869424T patent/LT3079719T/lt unknown
- 2014-12-09 JP JP2016557547A patent/JP6549143B2/ja active Active
- 2014-12-09 PT PT148694243T patent/PT3079719T/pt unknown
- 2014-12-09 IL IL298470A patent/IL298470A/en unknown
- 2014-12-09 BR BR112016013109-6A patent/BR112016013109B1/pt active IP Right Grant
- 2014-12-09 PL PL14869424T patent/PL3079719T3/pl unknown
- 2014-12-09 RS RS20191504A patent/RS59567B1/sr unknown
- 2014-12-09 EP EP19186014.7A patent/EP3611191A1/en active Pending
- 2014-12-09 CN CN201480067583.8A patent/CN105916519B/zh active Active
- 2014-12-09 SI SI201431406T patent/SI3079719T1/sl unknown
- 2014-12-09 HU HUE14869424A patent/HUE047283T2/hu unknown
- 2014-12-09 KR KR1020217032002A patent/KR20210125114A/ko not_active IP Right Cessation
- 2014-12-09 KR KR1020167018130A patent/KR102311761B1/ko active IP Right Grant
- 2014-12-09 WO PCT/US2014/069409 patent/WO2015089117A1/en active Application Filing
- 2014-12-09 DK DK14869424T patent/DK3079719T3/da active
- 2014-12-09 CA CA2930886A patent/CA2930886A1/en active Pending
- 2014-12-09 AU AU2014363944A patent/AU2014363944B2/en active Active
- 2014-12-09 NZ NZ720769A patent/NZ720769A/en unknown
- 2014-12-09 CN CN202111165428.8A patent/CN113861293A/zh active Pending
- 2014-12-09 KR KR1020237021876A patent/KR20230107382A/ko not_active Application Discontinuation
- 2014-12-09 CN CN202111165415.0A patent/CN114044825A/zh active Pending
- 2014-12-09 EP EP14869424.3A patent/EP3079719B8/en active Active
- 2014-12-09 SG SG10201808835QA patent/SG10201808835QA/en unknown
- 2014-12-09 SG SG11201604632PA patent/SG11201604632PA/en unknown
- 2014-12-09 ES ES14869424T patent/ES2758508T3/es active Active
- 2014-12-09 US US14/565,370 patent/US9546215B2/en active Active
2016
- 2016-05-16 IL IL245663A patent/IL245663B/en active IP Right Grant
- 2016-05-19 ZA ZA2016/03435A patent/ZA201603435B/en unknown
- 2016-12-07 US US15/372,268 patent/US20170209556A1/en not_active Abandoned
2019
- 2019-02-15 JP JP2019025337A patent/JP6963577B2/ja active Active
- 2019-05-17 US US16/416,085 patent/US20200054723A1/en not_active Abandoned
- 2019-11-13 HR HRP20192052TT patent/HRP20192052T1/hr unknown
- 2019-11-27 CY CY20191101242T patent/CY1122329T1/el unknown
2020
- 2020-02-25 JP JP2020029472A patent/JP2020078336A/ja not_active Withdrawn
- 2020-06-16 AU AU2020204016A patent/AU2020204016A1/en not_active Abandoned
2021
- 2021-01-13 IL IL280155A patent/IL280155A/en unknown
2022
- 2022-01-26 US US17/585,323 patent/US20220331412A1/en active Pending
- 2022-04-06 JP JP2022063368A patent/JP2022082715A/ja active Pending

Also Published As

Publication number	Publication date
JP2022082715A (ja)	2022-06-02
LT3079719T (lt)	2019-12-10
BR112016013109A2 (pt)	2017-09-26
SI3079719T1 (sl)	2019-12-31
EP3611191A1 (en)	2020-02-19
AU2014363944A1 (en)	2016-06-09
JP6963577B2 (ja)	2021-11-10
JP2020078336A (ja)	2020-05-28
SG11201604632PA (en)	2016-07-28
US20150203578A1 (en)	2015-07-23
JP2019076115A (ja)	2019-05-23
IL245663A0 (en)	2016-06-30
RS59567B1 (sr)	2019-12-31
NZ720769A (en)	2022-10-28
KR102311761B1 (ko)	2021-10-13
ES2758508T3 (es)	2020-05-05
CN114044825A (zh)	2022-02-15
EP3079719B8 (en)	2019-12-04
CN113861293A (zh)	2021-12-31
HRP20192052T1 (hr)	2020-02-07
AU2014363944B2 (en)	2020-03-26
CY1122329T1 (el)	2021-01-27
JP2017501744A (ja)	2017-01-19
AU2020204016A1 (en)	2020-07-02
KR20230107382A (ko)	2023-07-14
BR112016013109B1 (pt)	2021-05-11
US20200054723A1 (en)	2020-02-20
CN105916519B (zh)	2021-10-22
KR20160095113A (ko)	2016-08-10
ZA201603435B (en)	2020-08-26
PL3079719T3 (pl)	2020-05-18
JP6549143B2 (ja)	2019-07-24
KR20210125114A (ko)	2021-10-15
PT3079719T (pt)	2019-12-05
EP3079719A1 (en)	2016-10-19
HUE047283T2 (hu)	2020-04-28
IL280155A (en)	2021-03-01
EP3079719A4 (en)	2017-08-02
US9546215B2 (en)	2017-01-17
SG10201808835QA (en)	2018-11-29
CA2930886A1 (en)	2015-06-18
US20170209556A1 (en)	2017-07-27
IL298470A (en)	2023-01-01
WO2015089117A1 (en)	2015-06-18
EP3079719B1 (en)	2019-09-04
US20220331412A1 (en)	2022-10-20
CN105916519A (zh)	2016-08-31
IL245663B (en)	2021-02-28

Publication	Publication Date	Title
DK3079719T3 (da)	2019-11-18	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3227336T3 (da)	2019-09-16	Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK2970460T3 (da)	2020-06-02	Anti-IL-33-antistoffer og anvendelser deraf
CL2016001646A1 (es)	2017-06-09	Anticuerpos y fragmentos anti-vista
DK3083689T3 (da)	2020-08-03	Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK3280441T3 (da)	2021-11-15	Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3258951T3 (da)	2020-04-06	Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3026062T3 (da)	2020-10-12	Anti-pd-1-antistof og anvendelse deraf
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3215532T3 (da)	2020-01-02	Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3229838T3 (da)	2020-10-19	Anti-C10orf54-antistoffer og anvendelser deraf
DK3126388T3 (da)	2019-07-29	Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3027209T3 (da)	2020-11-02	Anti-Activin A-antistoffer og anvendelser deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK3406633T3 (da)	2022-03-28	Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
DK3086807T3 (da)	2022-09-19	Antistoffer og fremgangsmåder til anvendelse
DK3336106T3 (da)	2020-07-13	Anti-fcrh5-antistoffer
DK2956175T3 (da)	2017-11-27	Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK3381917T3 (da)	2021-10-18	Imidazopyridinforbindelser og anvendelser deraf
DK3083680T3 (da)	2020-03-16	Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3708583T3 (da)	2022-05-16	Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf